Join United Porphyrias Association and Portal Therapeutics to learn about the upcoming PATHWAY clinical trial for PORT-77, a new potential treatment for EPP & XLP. The webinar will explore:

• Current research in EPP and XLP.

• The science behind PORT-77.

• What Portal has learned from the Phase 2a GATEWAY study.

• The upcoming PATHWAY clinical study.

The Details

• Date: Wednesday, August 19, 2026

• Time: 6:00–7:00 PM ET (find your local time here)

• Location: Zoom- register below for link

The presentation will be recorded and available after the webinar.

PORT-77 is an investigational medicine and has not been approved by any regulatory authority.